CRIXIVAN CAPSULES 100MG

USFDA:Indinavir J05AE02(WHO) (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide 150378-17-9Y 5362440 DB00224Y 4515036Y 9MG78X43ZT C07051Y CHEBI:44032Y ChEMBL540914N 005824 MK1 (PDBe,RCSB PDB) DTXSID4043802 Interactive image CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](Cc2ccccc2)C(=O)N[C@H]3c4ccccc4C[C@H]3O)O)Cc5cccnc5 InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1YKey:CBVCZFGXHXORBI-PXQQMZJSSA-NY Indinavir(IDV; trade nameCrixivan, made byMerck) is aprotease inhibitorused as a component ofhighly active antiretroviral therapyto treatHIV/AIDS.‍‍‍‍‍‍​​​‍​​​​​​ It is soluble white powder administered orally in combination with other antiviral drugs. The drug prevents protease from functioning normally. Consequently, HIV viruses cannot reproduce, causing a decrease in the viral load. Commercially sold indinavir is indinavir anhydrous, which is indinavir with an additional amine in the hydroxyethylene backbone. This enhances its solubility and oral bioavailability, making it easier for users to intake. It was synthetically produced for the purpose of inhibiting the protease in the HIV virus. It is no longer recommended for use in HIV/AIDS treatment due to its side effects. Furthermore, it is controversial for many reasons starting from its development to its usage. It was patented in 1991 and approved for medical use in 1996,on March 13 by theUnited States Food and Drug Administration,on October 1 by the AustralianTherapeutic Goods Administrationand on October 4 by theEuropean Medicines Agency.